167 related articles for article (PubMed ID: 16358237)
21. [Anderson-Fabry's disease: diagnostic problems, therapeutic relevance, and clinical experience in the treatment of the disease with enzyme replacement therapy in nephropathic patients].
Cianciaruso B; Pisani A; Andreucci MV; Parente N; Andria G; Federico S; Sabbatini M; Sessa A
G Ital Nefrol; 2003; 20(2):113-9. PubMed ID: 12746795
[TBL] [Abstract][Full Text] [Related]
22. [Fabry disease].
Jakubowska E; Ryba M; Hruby Z
Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement in Anderson-Fabry disease.
Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
[No Abstract] [Full Text] [Related]
24. [Fabry disease: new clinical research--current therapeutic perspectives].
Beck M
Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
[No Abstract] [Full Text] [Related]
25. [Fabry disease : diagnosis and treatment].
Üçeyler N; Sommer C
Schmerz; 2012 Sep; 26(5):609-19. PubMed ID: 23052995
[TBL] [Abstract][Full Text] [Related]
26. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
27. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M; Brand E
J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
[No Abstract] [Full Text] [Related]
28. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
30. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
31. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
32. Anderson-Fabry disease.
Di Toro A; Favalli V; Arbustini E
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e1-e5. PubMed ID: 29538136
[No Abstract] [Full Text] [Related]
33. [Fabry disease in cardiology: Diagnosis and therapeutic approaches].
Çavuşoğlu Y; Özpelit E; Arslan N; Demir M; Kahveci G; Onay H; Ökçün EÖB; Tufekcioglu O; Tülüce SY; Yıldırım GK
Turk Kardiyol Dern Ars; 2020 Dec; 48(Suppl 2):1-42. PubMed ID: 33476309
[TBL] [Abstract][Full Text] [Related]
34. Fabry disease in an oligosymptomatic male.
Altarescu G; Elstein D
Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
[No Abstract] [Full Text] [Related]
35. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
[TBL] [Abstract][Full Text] [Related]
36. Cardiac involvement in Anderson-Fabry disease.
Cauti FM; O'Mahony C; Pantazis A
BMJ Case Rep; 2010 Aug; 2010():. PubMed ID: 22767366
[TBL] [Abstract][Full Text] [Related]
37. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
[TBL] [Abstract][Full Text] [Related]
38. [Management of Fabry disease].
Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
[TBL] [Abstract][Full Text] [Related]
39. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
Mignani R; Cagnoli L
J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
[TBL] [Abstract][Full Text] [Related]
40. Case report: is low α-Gal enzyme activity sufficient to establish the diagnosis of Fabry disease?
Biagini G; Almeida ACSF; Almeida TVR; Silva CAB; Castro BF; Reche TC; Dabinski AC; Barreto FC
J Bras Nefrol; 2017; 39(3):333-336. PubMed ID: 29044343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
